SEC filing record
Primary Source · SEC.gov

Retension Pharmaceuticals, Inc.

2025 vintageRule 506(b)Filing record

Built from the SEC filing index the day the filing landed. The figures below are the issuer's own from Form D; AltStreet's analysis, sponsor link and data flags follow when the entity is enriched.

Latest signalNew Form D filerForm D · 2025-05-064 events: 1 new form d filer, 1 sold increased, 1 investors increasedLast filing 2025-05-06

Raised

$12M

Investors

98

Min Invest

None stated

AltStreet Verified Issuer badge

Is this your company or fund? Claim this page free, or verify it and carry the Verified Issuer mark.

What this filing shows

·

Every sentence is a value as filed on SEC Form D

Retension Pharmaceuticals, Inc. is a Delaware corporation that first filed a Form D on December 5, 2023 and most recently amended it on May 6, 2025 in the Pharmaceuticals industry group. The offering claims Rule 506(b) and covers equity. Retension Pharmaceuticals, Inc. reported $12,288,567 sold from 98 investors of a $20,000,000 total offering as of the Form D filed May 6, 2025. The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. The filing reports no non-accredited investors. The filing lists the minimum investment as $0, meaning no minimum was stated. The Form D names Collage Venture Partners, LLC (CRD 316063), associated with None; Stonehaven, LLC (CRD 118913), associated with None as recipients of sales compensation soliciting in all states. Sales commissions are reported as $701,374 and finders' fees as $0. Form D allows these to be estimates. The issuer's address of record is C/O Redux Therapeutics, LLC, 902 Turkey Run Road, Mclean, VA 22101.

EDGAR Filing Data

Form D — Primary Source

View on SEC.gov
CIK Number0002002988
Entity NameRetension Pharmaceuticals, Inc.
ExemptionRule 506(b)
What the exemption meansRule 506(b) of Regulation D: securities may be sold to an unlimited number of accredited investors and up to 35 non-accredited investors who meet the rule's sophistication standard, without general solicitation or advertising.
Entity TypeCorporation
Jurisdiction of OrganizationDelaware
Issuer AddressC/O Redux Therapeutics, LLC, 902 Turkey Run Road, Mclean, VA 22101
Phone(703) 624-2024
Industry / Fund TypePharmaceuticals
Securities TypeEquity
First Sale DateApril 22, 2025
Filing DateMay 6, 2025
Accession Number0002002988-25-000002
Total Offering Amount$20,000,000
Total Amount Sold$12,288,567
Amount Remaining$7,711,433
Total Investors98
Non-Accredited InvestorsNone
Minimum Investment$0 (no stated minimum)
Offering DurationOne year or less
Sales Commissions$701,374 (to Collage Venture Partners, LLC and 1 other)
Finders' Fees$0
Revenue RangeDecline to Disclose
State (Issuer Address)VA
Amendment Count3 filings on record

Filings on Record

Every filing AltStreet's ledger holds for this CIK, newest first. Each opens the SEC archive folder.

In the Terminal

Filing events

4

latest May 6, 2025

Critical / warning

0 / 0

2 watch · 2 info

Statements extracted

0

none on file

NAV prints

0

none on file

Offering chains

2

lapsed

Latest event New filer · May 6, 2025

SEC.gov
Open in the terminal Watch this issuerInvestor $149/mo unlocks the values; Pro $349/mo adds the universe.

Investor

  • 4 filing events with values and deltas, latest 2025-05-06, and alerts on the next one
  • 2 offering timelines: velocity, share raised, first-sale lag, stalled flags

Pro

  • This issuer against its cohort: rank by velocity and share raised among offerings filed the same quarter
  • The same events, statements and NAV moves across every issuer, screenable, with unlimited watches and CSV

Counts and dates above are the free record. The values, the series and the comparisons are the seat. Loading your view…

Related Persons (Form D)

Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.

Eric Keller

Executive Officer, Director · McLean, VA

Michael Berendt

Director · McLean, VA

Donald Olds

Director · McLean, VA

Placement Agents and Sales Compensation (Form D)

Who the issuer reported paying to sell the securities (Form D Item 12), with the FINRA registration number the filer gave. Source: SEC.gov.

Collage Venture Partners, LLCCRD 316063 on BrokerCheck

Associated broker-dealer: None · Miami Beach, FL · Soliciting in all states

Stonehaven, LLCCRD 118913 on BrokerCheck

Associated broker-dealer: None · New York, NY · Soliciting in NY

Questions About Retension Pharmaceuticals, Inc.

Each answer is built from the values on the SEC filing and the AltStreet ledger, not from the issuer's marketing.

What is Retension Pharmaceuticals, Inc.?

Retension Pharmaceuticals, Inc. is a Delaware corporation that filed a Form D with the SEC on May 6, 2025 in the Pharmaceuticals industry group. The filing claims Rule 506(b) for an offering of equity.

Is Retension Pharmaceuticals, Inc. legit?

AltStreet does not rate legitimacy; it reports the public record. Retension Pharmaceuticals, Inc. filed a Form D with the SEC on May 6, 2025 claiming Rule 506(b). A Form D is a notice of an exempt offering, not a review or approval of it. The newest notice reports $12,288,567 sold to 98 investors. AltStreet's enforcement record (SEC, FINRA and state actions) shows no action naming the issuer as of today. Before investing, confirm the filing on EDGAR, check the seller's registration on FINRA BrokerCheck, and read the offering documents, which a Form D does not include.

Is Retension Pharmaceuticals, Inc. registered with or approved by the SEC?

No. A Form D is a notice that an issuer is selling securities under an exemption from registration, and the SEC does not review, approve, or pass on the merits of the offering. The filing shows that Retension Pharmaceuticals, Inc. claimed Rule 506(b) and disclosed the items the form requires, such as the amount sold, the minimum investment, related persons, and anyone paid to sell the securities. It does not verify the issuer's claims or its business.

How much has Retension Pharmaceuticals, Inc. raised?

Retension Pharmaceuticals, Inc. reported $12,288,567 sold from 98 investors of a $20,000,000 total offering as of the Form D filed May 6, 2025.

Who can invest in Retension Pharmaceuticals, Inc.?

The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. The filing reports no non-accredited investors. The filing lists the minimum investment as $0, meaning no minimum was stated.

What is the minimum investment in Retension Pharmaceuticals, Inc.?

The Form D lists the minimum investment as $0, which means the issuer did not state a minimum on the form. The offering documents, not the Form D, set the actual subscription terms.

Who is selling Retension Pharmaceuticals, Inc. and how are they paid?

The Form D names Collage Venture Partners, LLC (CRD 316063), associated with None; Stonehaven, LLC (CRD 118913), associated with None as recipients of sales compensation soliciting in all states. Sales commissions are reported as $701,374 and finders' fees as $0. Form D allows these to be estimates.

Who is behind Retension Pharmaceuticals, Inc.?

The Form D lists 3 related persons: Eric Keller, executive officer, director; Michael Berendt, director; Donald Olds, director. Form D Item 3 requires executive officers, directors, and promoters of the issuer to be listed.

Where is Retension Pharmaceuticals, Inc. located?

The issuer's address on its SEC filings is C/O Redux Therapeutics, LLC, 902 Turkey Run Road, Mclean, VA 22101. Its phone number of record is (703) 624-2024. It is organized under the laws of Delaware.

How long is the Retension Pharmaceuticals, Inc. offering open?

The issuer indicated that the offering is not intended to last more than one year. An issuer must amend its Form D annually while a continuing offering stays open; 1 amendment is on record for this CIK.

What is Retension Pharmaceuticals, Inc.'s revenue?

The issuer declined to disclose its revenue range on the Form D, which the form permits.

AltStreet Verified Issuer badge

Is this your company or fund?

Free claim: add your contact details, website, team and a description to this page. The filed facts stay as filed.

Verified Issuer, $480 a year: AltStreet checks the identity of your company and the authority of the person claiming it against your filings, confirms your contact details on a stated date and again at each renewal, and marks the page so people researching you find a current, attributed profile beside the public filing record. It is not a review of any offering.

Data Methodology

Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.